Category: 3. Business

Animals

Experiments complied with the ARRIVE procedures and the ethical guidelines of the European Council Directive (2010/63/EU). Experimental approval was obtained from the Italian Ministry of Health. Male and female C57BL/6N (Charles River, Italy) and female B6.129P2(Cg)-Cx3cr1^tm1Litt/J (CX₃CR-1^GFP knock-in/knock-out; Jackson Laboratory Strain #:005582) mice were used at 2–3 months of age. Heterozygous male Tg2576 mice (Taconic #APPSWE—Model 1349 tg/wt; [41]) and their Wild-Type (WT) littermates (mice with the same strain and genetic background of Tg2576, negative for APPSWE overexpression—Taconic #APPSWE—Model 1349 wt/wt) were used at 6–7 months of age.

All mice were housed with ad libitum food and water, with a 12 h light/dark cycle. Mice were housed in cages of 3–4 individuals and all cages were equipped with the same environmental enrichment.

Stereotaxic injections

Mice were anaesthetized with Rompun (20 mg/mL, 0.5 mL/kg; Bayer) and Zoletil (100 mg/mL, 0.5 mL/kg; Virbac; intraperitoneally i.p.) and positioned in a stereotaxic apparatus.

For Caspase-3 (Casp3) mice (C57BL/6N, CX₃CR-1^GFP or Tg2576 mice), we infused a mix of Adeno-Associated Viruses (AAVs; 0.5 µL each, flux 80 nL/min [42]: (i) AAV1-THp-iCre (5 × 10¹² viral particles/mL; Vector Biolabs) and (ii) AAV5-flex-taCasp3-TEVp (4.2 × 10¹² viral particles/mL; UNC Vector core, gift from Nirao Shah) in the left VTA (AP: −3.2, ML: −0.35, DV: −4.4; 43), to lesion Tyrosine Hydroxylase-positive (TH⁺) neurons in the VTA and Substantia Nigra pars compacta (SNpc) and 5-HT⁺ neurons in the interpeduncular nucleus (IPN). Sham mice were injected only with the AAV1-THp-iCre virus.

In a separate cohort of C57BL/6N mice, the AAV1-THp-iCre + AAV5-flex-taCasp3-TEVp mix (0.125 µL each, flux 25 nL/min) were injected in the IPN (thereafter: Casp3^IPN; AP: −3.5, ML: 0, DV: −4.7; [43]) to lesion the 5-HT⁺ neurons of the IPN while leaving intact the TH⁺ neurons of the VTA/SNpc. Sham mice were injected only with the AAV1-THp-iCre virus (Sham^IPN).

To confirm the ectopic expression of TH promoter-driven AAVs, a set of C57BL/6N mice were infused in the VTA with a mix (0.5 µL each, flux 80 nL/min) of (i) AAV1-THp-iCre and (ii) AAV5-EF1α-DIO-eYFP (4.0 × 10¹² viral particles/mL; UNC Vector core, gift from Karl Deisseroth). eYFP expression was then analyzed with confocal microscopy (see below).

For 6-hydroxy-dopamine (6OHDA) lesion (C57BL/6N mice), 6OHDA (Sigma-Aldrich; 7.6 mg/mL, calculated as free-base) was dissolved in 0.2 mg/mL ascorbic-acid (Tocris) prepared in 0.9% saline, and continuously kept on ice. Each mouse was injected with 2.5 μg in 0.4 µL (flux 40 nL/min) unilaterally in the left VTA. Thirty minutes before surgery, mice received 10 mL/kg (2.85 mg/mL as free base, i.p.) of the norepinephrine (NE) reuptake-inhibitor desipramine-hydrochloride (Sigma-Aldrich), to prevent NE fiber degeneration. Control mice were injected with Saline.

C57BL/6N and CX₃CR-1^GFP mice received the intracerebral injection at 2 months of age. Tg2576 mice were injected at 6 months of age. All mice were used 30 days following injection to ensure steady-state lesion. A separate set of Casp3 and Sham were used at 72 h following lesion; in these mice we examined the levels of Casp3 protein in the midbrain (see below).

For retrograde labelling, red retrobeads (120 nL; 12 nL/min; Lumafluor) were injected bilaterally in the Nucleus Accumbens (NAc) medial shell (AP: 1.8, ML: ± 0.4, DV: 4.1), NAc core (AP: 1.5, ML: ± 0.9, DV: 4.1) and dorsal striatum (AP: 1.0, ML: ± 1.6, DV: 2.3). Mice were examined 1 month after surgery.

For all infusions we used 1 μL Hamilton syringes (Model Neuros7001) mounted on a Pump-11 Elite Nanomite (Harvard Apparatus). When possible, the accuracy of the injection site was controlled by immunofluorescence analysis; mice with misplaced injection were excluded.

Drug treatments

Animals were injected with L-DOPA (i.p., 10 mg/kg; Sigma-Aldrich) plus benserazide (12 mg/kg; Sigma-Aldrich) [44], or with A68930-hydrochloride (5 mg/kg; Santa Cruz), once a day for 4 or 7 days, respectively; 0.9% saline was used as control (vehicle); experiments were performed 1 h after the last injection.

Fluoxetine-hydrochloride (30 mg/kg; Tocris) was dissolved in water and delivered ad libitum in drinking bottles wrapped in tin-foil for 30 days, starting immediately after surgery. Normal drinking water was used as control.

Immunofluorescence

Anaesthetized mice (Rompun/Zoletil) were transcardially-perfused with Phosphate Buffer (PB; 0.1 M, pH 7.4) followed by 4% paraformaldehyde in PB. Brains were postfixed in 4% paraformaldehyde for at least 4 h, dehydrated and cryoprotected in 30% sucrose in PB at 4 °C until sinking. Thirty μm-thick coronal sections were cut with a cryostat, and slices were collected in PB-sodium azide 0.02%. All analyses were performed in the left hemisphere, ipsilateral to the lesion.

Slices were incubated with primary antibodies in PB containing 0.3% Triton X-100 overnight at 4 °C for TH, Iba1, GFAP, hippocampal 5-HT transporter (SERT) and striatal TH/DA transporter (DAT)/SERT staining, or 3 nights for IL-1β/Iba1, IL-18/Iba1, IL-18 Receptor (IL-18R)/GFAP, p-Nuclear Factor kappa B (p-NFκB)/S100β and Microtubule-Associated Protein 2 (MAP2).

For 5-HT, slices were incubated with primary antibodies in PB containing 0.5% Triton X-100 and 10% donkey-serum for 2 nights at 4 °C.

For hippocampal TH⁺/NE transporter-positive (NET⁺) fibers, sections were incubated in citrate buffer (10 mM sodium-citrate, pH 6.0 containing 0.05% Tween-20; 20 min, 75 °C), rinsed in PB, immersed in blocking solution (5% donkey serum, 0.2% Triton X-100 in PB; 1 h, RT), and incubated with primary antibody in the same solution (overnight at 4 °C; [45]).

For NLRP3/Iba1/GFAP and NLRP3/Iba1 staining, sections were pretreated with 50% methanol (15 min, RT) immersed in blocking solution (3% bovine serum albumin, 0.1% Triton X-100 in PB, 30 min, RT) and incubated with primary antibodies in PB with 0.1% Triton X-100 (2 nights, 4 °C).

For Iba1/CD68, slices were permeabilized using 0.5% Triton X-100 in PB (45 min, RT), incubated in blocking solution (2% bovine-serum albumin, 0.5% Triton X-100 in PB; 1 h, RT) and exposed to primary antibodies in blocking solution (2 nights, 4 °C).

For C3/GFAP, slices were immersed in blocking solution (5% donkey serum, 0.1% Triton X-100 in PB; 1 h, RT) and then incubated with primary antibodies in 1% donkey serum, 0.1% Triton X-100 in PB (overnight, 4 °C).

For C3aR/Iba1/NeuroTrace analysis, slices were incubated in blocking solution (3% bovine-serum albumin, 5% goat serum, 0.5% Triton X-100 in PB; 1 h, RT) and then with primary antibodies in blocking solution (overnight, 4 °C).

For tau staining (AT8), slices were pretreated with 50% methanol (15 min, RT), immersed in blocking solution (3% bovine serum albumin, 0.1% Triton X-100 in PB) with M.O.M.® (Mouse on Mouse) Blocking Reagent (1:1000; Vector laboratories, #MKB-2213–1; 1 h, RT) and then incubated with primary antibodies in 0.1% Triton X-100 in PB (2 nights, 4 °C).

For Aβ staining (6E10), sections were pretreated with M.O.M.® (1:1000; 2 h, RT) diluted in permeabilization solution (PB with 0.3% Triton X-100) and incubated with primary antibodies overnight at 4 °C in permeabilization solution.

For eYFP expression, coronal sections containing the midbrain, Raphe and LC were stained with TH/5-HT, 5-HT and TH, respectively as described above.

For every immunofluorescence protocol, after primary antibody, slices were incubated with secondary antibodies in the same solution of primary antibody (2 h, RT) and counterstained with Blue-Fluorescent Nissl-Stain (NeuroTrace 1:200; Invitrogen) or DAPI (1:1000, Serva).

After mounted, slices were examined using a Nikon Eclipse Ti2 confocal microscope. The labeling specificity was confirmed by omission of primary antibodies and use of normal serum instead (negative controls). For quantitative analysis, images were processed simultaneously and analyzed with Fiji-ImageJ (http://imagej.nih.gov/ij/): after 8-bit conversion and background subtraction, the signal was quantified by measuring the relative fluorescence intensity. The F/A ratio defines mean fluorescence intensity (F) over surface area (A).

For analysis of fiber density and intensity, and protein levels, images were acquired with a 20x-objective by Z-stacks, then processed by maximum-intensity projection. All samples were captured with identical Z-stack thickness and laser settings within each analysis.

TH⁺/DAT⁺/SERT⁺ fiber intensity was quantified by setting 16 frames (100 × 100 pixel). The total fiber number per 250 µm was counted manually [45, 46].

CD68, NLRP3, IL-1β and IL-18 protein levels were measured within Iba1⁺ cells.

Automated total cell counts and analysis of overlapping regions between markers to assess colocalization were performed in Imaris XT software (Bitplane AG, Oxford Instruments, Abingdon-on-Thames, UK). For all double-positive cell counting analyses, the Surfaces function was used. Briefly, after applying background subtraction and automatic thresholding, to retain only objects within lower and upper threshold Limits, and splitting of touching objects to separate individual cells, colocalization between markers was quantified using the Overlapped Volume Surfaces option. Complement component 3 (C3) levels were quantified within GFAP⁺ cells, while MAP2 intensity was quantified by setting 12 frames (90 × 90 pixel) over the stratum radiatum. Intracellular Aβ levels were quantified by setting 10 randomly-distributed frames on the hippocampal CA1 pyramidal layer (70 × 70 pixel).

To analyze the number of Aβ plaques and the AT8⁺ area in the hippocampus, we acquired Z-stack large images with a 20x-objective. The mean number of 6E10⁺ plaques in the hippocampus from at least 3 slices/animal was quantified. To calculate AT8⁺ area, the hippocampus was manually defined, and automatic brightness thresholding was used to delineate the positive area. Hippocampal AT8⁺ area was expressed as ratio of total area analyzed in each slice/animal (modified from [47]). Intracellular AT8 levels were quantified by Z-stack with 60x-oil objective and by setting 1 frame (20 × 20 pixel).

For all analyses, quantification was done on 4 slices/mouse. Data were then averaged per mouse for figures and statistical analysis.

Primary antibodies: 5-HT (1:500; ImmunoStar #20080; RRID:AB_572263), AT8 Ser202/Thr205 (1:200; Invitrogen #1020; RRID:AB_223647), C3 (1:300; Novus Biologicals #NB200-540; RRID:AB_2744548), C3aR (1:200; HycultBiotech #HM3028; RRID:AB_2131309), CD68 (1:400; Biorad #MCA1957; RRID:AB_322219), DAT (1:400; Chemicon #MAB369; RRID:AB_2190413), GFAP (1:1000; Millipore #AB5804; RRID:AB_2109645), GFAP (1:1000; DAKO #Z0334; RRID:AB_2314535), hAPP695 (6E10) (1:500; BioLegend #803001; RRID: AB_2564653), Iba1 (1:600; Wako #019–19741; RRID:AB_839504), AIF-1/Iba1 (1:600; Novus Biologicals #NB100-1028; RRID:AB_3148646), IL-1β (1:200; R&D #AF-401-NA; RRID:AB_416684), IL-18 (1:300; MBL #D047-3; RRID:AB_592016), IL-18R⍺/IL-1 r5 (1:100; R&D #AF856; RRID:AB_355664), MAP2 (1:500; Invitrogen #MA5-12,826; RRID:AB_10976831), NET (1:500; Atlas Antibodies #AMAb91116; RRID:AB_2665806), NLRP3 (1:200; Adipogen #AG-20B-0014; RRID:AB_2490202), p-NFκB (Ser536) (1:200; Cell Signaling #3033; RRID:AB_331284), S100β (1:500; SYSY #287 006; RRID:AB_2713986), SERT (1:500; Millipore #PC177L; RRID:AB_2122553), TH (1:1000; Millipore #MAB318; RRID:AB_2201528), TH (1:500; Millipore #AB152; RRID: AB_390204).

Secondary Antibodies (Thermo Fisher): Alexa Fluor-488 donkey anti-rabbit (1:200; #A-21206; RRID:AB_2535792), Alexa Fluor-555 donkey anti-rabbit (1:200; #A31572; RRID:AB_162543), Alexa Fluor-647 goat anti-rabbit (1:200; #A-31573; RRID:AB_2536183), Alexa Fluor-488 donkey anti-mouse (1:200; #R37114; RRID:AB_2556542), Alexa Fluor-555 donkey anti-mouse (1:200; #A31570; RRID:AB_2536180), Alexa Fluor-488 donkey anti-rat (1:200; #A21208; RRID:AB_2535794), Alexa Fluor-647 goat anti-rat (1:200; #A-21247; RRID:AB_141778), Alexa Fluor-488 donkey anti-goat (1:200; #A-11055; RRID:AB_2534102), Alexa Fluor-647 donkey anti-goat (1:200; #A-21447; RRID:AB_141844), Alexa Fluor-555 goat anti-chicken (1:200; # A-21437; RRID:AB_2535858).

Exclusively for the representative confocal images, after the quantitative analysis, LUTs were equally increased at the same level for all groups of a given experiment. Quantitative analyses were performed on raw images.

Stereology

Immunofluorescence sections were used to estimate: TH⁺ neurons in the left SNpc, VTA and LC, 5-HT⁺ neurons in the entire IPN; 5-HT⁺ neurons in the dorsal (dRaphe) and medial Raphe (mRaphe); Iba1⁺ cells in the hippocampus, dorsal and ventral striatum and GFAP⁺ cells in the hippocampus. The area boundaries for VTA/SNpc/LC were defined by TH, the IPN/dRaphe/mRaphe by 5-HT, the dorsal and ventral striatum and hippocampus by DAPI staining, using the 5x-objective, in accordance to Paxinos guidelines [43].

We applied an optical fractionator stereological design using the Stereo Investigator System (MBF Bioscience). A stack of MAC5000 controller modules (Ludl Electronic Products, Ltd) was interfaced with a Zeiss Microscope Axio Imager KMAT with a motorized stage and a Zeiss Axiocam 506 mono with Working High End PC. A 3D-optical fractionator counting probe (x, y, z dimension 50 × 50 × 25 μm for TH⁺ neurons, 70 × 70 × 25 μm for 5-HT⁺ neurons and 100 × 100 × 25 μm for glia cells) was applied. Cells were marked with a 100x-oil-(VTA/SNpc) or a 40x-objective (neurons in LC/IPN/dRaphe/mRaphe; glia cells in hippocampus and striatum).

The total cell number was estimated according to the formula (Eq. 1):

where SQ represents the cell number counted in all optically sampled fields of the ROI, ssf is the section sampling fraction, asf is the area sampling fraction and tsf is the thickness sampling fraction.

Morphological analysis

Microglia were imaged with a Zeiss Microscope Axio Imager KMAT with motorized stage and a camera connected to Neurolucida software (7.5v; MBF Bioscience) for quantitative 3D-analysis of the entire cell [48, 49]. Only non-overlapping cells that showed clear soma and branching were analyzed. Soma area and perimeter were measured; Sholl analysis included counting the number of dendritic intersections, nodes and endings, and dendritic lengths at fixed distances from the soma in 10 μm-spaced concentric circles originating from the soma. Analysis was done with 100x-oil objective. Nine representative cells/animal were analyzed randomly and data were averaged for each mouse.

Total protein extraction and Western-blot analysis

The ipsilateral hippocampus was dissected from the entire brain and stored at −80 °C until the day of the experiment. The ipsilateral midbrain was isolated from 500 μm-frozen slices using a biopsy punch. Tissue was homogenized in RIPA buffer containing (in mM): 50 Tris–HCl pH 7.5, 150 NaCl, 5 MgCl₂, 1 EDTA, 1% Triton X-100, 0.25% sodium deoxycholate, 0.1% SDS, 1 sodium-orthovanadate, 5 b-glycerophosphate, 5 NaF and protease inhibitor cocktail; samples were then sonicated four times (five strokes of 0.5 pulse/s) and incubated on ice for 30 min [50]. Samples were centrifuged (13000 g, 20 min, + 4 °C) and the supernatant’s protein concentration was determined by the Bradford method. Proteins were applied to SDS-PAGE and electroblotted on a polyvinylidene-difluoride membrane. Blotting analysis was performed using a chemiluminescence detection kit. The relative levels of immunoreactivity were determined by densitometry using ImageJ.

Primary antibodies: Caspase-3 (1:500; Cell Signaling Technology; #9662s; RRID:AB_331439), Glycogen Synthase Kinase 3β (GSK3β; 1:1000; Cell Signaling Technology; #9832s; RRID:AB_10839406); p-GSK3β (Ser9) (1:1000; Cell Signaling Technology; #9336s; RRID:AB_331405); JNK (1:1000; Cell Signaling Technology; #9252s; RRID:AB_2250373); p-JNK (Thr183/Tyr185) (1:1000; Cell Signaling Technology; #9251s; RRID:AB_331659); p-p38 (Thr180/Tyr182) (1:1000; Cell Signaling Technology; #4511s; RRID:AB_2139682); p38 (1:1000; Cell Signaling Technology, #8690s; RRID:AB_10999090); TH (1:500; Abcam, #ab112; RRID:AB_297840); β-Tubulin (1:1000; Biolegend; #801201; RRID:AB_2313773). All primary antibodies were incubated overnight except for β-Tubulin (2 h).

Secondary antibodies: goat anti-mouse IgG (1:3000; Bio-Rad; #1706516; RRID:AB_11125547), goat anti-rabbit IgG (1:3000; Bio-Rad; #1706515; RRID:AB_2617112).

Membranes were stripped using Re-Blot Plus Strong Solution (Millipore; 15 min, RT). Both groups (Shan vs Casp3; Tg Sham vs Tg Casp3) were analyzed simultaneously.

Microglia sorting, RNA isolation and RNA-sequencing

Microglia sorting

Hippocampus from Sham and Casp3 CX₃CR-1^GFP mice (Sham: n = 3; Casp3: n = 5 mice) was dissociated into single-cell suspensions using Adult Brain Dissociation kit (Miltenyi Biotec, #130–107-677) according to the manufacturer’s instructions. Briefly, each mouse was transcardially perfused with 1 × D-PBS^+/+. The hippocampus of each Sham or Casp3 CX₃CR-1^GFP mouse was isolated and added in half brain of a C57BL/6N mouse, to increase the quantity of tissues to dissociate. Tissues were then cut into small pieces and enzymatically and mechanically dissociated on the gentle MACS Octo Dissociator with Heaters (Miltenyi Biotec, #130–096-427) using the 37C_ABDK_01 program. Following dissociation, samples were resuspended and passed through a prewet 70 μm MACS SmartStrainer (Miltenyi Biotec, #130–110-916,) and centrifuged at 300 g for 10 min at 4 °C. Following centrifugation, the supernatant was discarded, and the debris were removed using the Debris Removal solution (Miltenyi Biotec, #130–109-398) provided by the kit. Finally, cells were resuspended in 100 μL of Running Buffer and stained for 30 min at 4 °C protected from light with the following antibodies: CD11b Monoclonal Antibody (M1/70) PE-Cyanine7 (1:100; Invitrogen, #25-0112-82; RRID: AB_469588) and PerCP anti-mouse CD45 Antibody (1:100; BioLegend #103130; RRID: AB_893339). To exclude dead cells, LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (1:100; Invitrogen, #L34957) was used. Cells were washed with Running Buffer and pelleted at 1000 g for 10 min at 4 °C. Then, cells were resuspended in 400 µL of Running Buffer. Afterward, the samples were taken to FACS and the gating strategy was set to CD11b⁺CD45⁺eGFP⁺ for isolation of microglia from Sham or Casp3 CX₃CR-1^GFP hippocampi. The sorting purity was to be approximately 97%.

RNA extraction and mRNA-Seq

Total RNA from isolated microglia was purified via the spin-colum based “Total RNA purification Plus Micro Kit” (Norgen Biotek, #48500), following the manufacturer instructions.

Low-input mRNA-Seq was performed by Igatech Service (Udine, Italy). Briefly, RNA samples were quantified, and quality tested by TapeStation RNA assay (Agilent Technologies). Libraries were generated using the Ovation SoLo RNA-seq Library Preparation kit (Tecan Genomics) following the manufacturer’s instructions. Final Libraries were checked with Qubit 3.0 Fluorometer (Invitrogen) and Agilent Bioanalyzer DNA assay. Libraries were then barcoded for multiplexing and sequenced on paired-end 150 bp mode on NovaSeq 6000 (Illumina) at a depth of 30 million reads. Base calling and demultiplexing was performed with Illumina BCL Convert v3.9.31. Lower quality bases and adapters were removed by Cutadapt v1.11 software [51]. Reads were aligned on reference GRCm39.112 genome with STAR [52] using default parameters. Assembling and quantitation of full-length transcripts representing multiple spliced variants for each gene locus was performed by Stringtie [53] using default parameters.

Differentially expressed genes (DEGS) were identified with DESeq2 [54]. The ToppGene suite was used with default settings to identify functional enrichment in the DEG lists (http://toppgene.cchmc.org).

High Performance Liquid Chromatography (HPLC)

Quantification of hippocampal monoamines (DA, 5-HT, NE), and relative metabolites (DOPAC and HVA for DA, 5-HIAA for 5-HT, MOPEG for NE) was performed using an HPLC system (UltiMate® 3000, Thermo Fisher) coupled with Coulochem electrochemical detection (6011RS Ultra Coulometric Analytical Cell, Thermo Fisher). After animal sacrifice, the left hippocampus was rapidly dissected on ice and immediately stored at −80 °C until analysis. On the day of analysis frozen samples were homogenized on ice with 0.05 M HClO₄ and antioxidant solution (containing in mM: 0.27 Na₂EDTA, 100 acetic acid, 0.0125 ascorbic acid) in a 4:1 ratio. The homogenate was mechanically lysed, sonicated on ice and centrifuged (10000 rpm, 20 min, 4 °C). The supernatant was transferred into a new tube and the pellet was weighed. 20 µL of each sample were injected onto the HPLC-ECD (run-time: 60 min; flow-rate: 0.6 mL/min). Standards of each metabolite were prepared fresh on the day with same solutions and quantities as for tissue samples. The chromatographic separation was performed on a Hypersil GOLD aQ-C18 column (150 × 3 mm, 5 µm) fitted with an aQ-C18 drop-in guard pre-column (10 × 3 mm, 5 µm) maintained at 37 °C. The mobile phase consisted of 5% methanol and buffer solution (0.1 M Na-Phosphate, 0.1 mM Titriplex® III and 0.5 μM 1-Octanesulfonic-Acid Na-salt, pH 3.6 adjusted with 85% Ortho-Phosphoric-acid), filtered through a 0.22 µm cellulose-ester membrane (Millipore). The potential applied to both dual-inline flow-through micro-porous graphitic carbon-working electrodes was set at + 450 mV, with 1 nA-gain for ECRS1 and 10 nA-gain for ECRS2. The chromatograms were integrated with Chromeleon™ Software (7.0v; Thermo Fisher). The sample concentration of metabolites was calculated from the corresponding peak height, normalized to the pellet weight.

Brain slicing and electrophysiology

Following head dislocation, mice were decapitated and the brain was rapidly removed; 300 μm-thick parasagittal slices containing the left dorsal hippocampus were cut (Leica VT1200S vibratome) in oxygenated (95% O₂, 5% CO₂) ice-cold sucrose-based solution (in mM: 3 KCl, 1.25 NaH₂PO₄, 26 NaHCO₃, 10 MgSO₄, 0.5 CaCl₂, 25 glucose, 185 sucrose; ~ 300 mOsm, pH 7.4). Brain slices were left to recover in artificial Cerebro-Spinal Fluid (aCSF; containing in mM: 124 NaCl, 1.25 NaH₂PO₄-H₂O, 26 NaHCO₃, 3 KCl, 10 Glucose, 1 MgSO₄, 2 CaCl₂, ~ 300 mOsm, pH 7.4) at 32–34 °C for 40 min, and moved at RT for at least 30 min before recording [55].

For recording, each slice was placed under an Olympus BX51WI microscope and perfused with oxygenated aCSF (3-4 mL/min, 30-32 °C). The hippocampus was visualized with infrared differential-interference-contrast at 4x.

Recordings were performed using a MultiClamp700B amplifier, digitized with Digidata1550B and computer-saved with pClamp11 (Molecular Devices). Patch-pipettes (3–5 MΩ), filled with aCSF, were pulled from TW150F-4 glass tubes (WPI). Field excitatory postsynaptic potentials (fEPSPs), recorded in the stratum radiatum, were induced with Schaffer collateral stimulation (100 μs), acquired at 20 kHz and filtered off-line with a 10 kHz low-pass Bessel filter. Input–Output (I/O) curves of fEPSP slopes were obtained at 10 μA-stepped increasing stimulation every 30 s. The Paired-Pulse Ratio (PPR) was evaluated with pairs of stimuli (20–1000 ms interval), at half-maximal stimulation. For Long-Term Potentiation (LTP), after 20 min of test stimulation (half-maximal intensity, every 30 s) to assess slope stability, the slice was challenged with two trains at 100 Hz (1 s duration, 20 s interval) followed by test stimulation for 1 h. The LTP magnitude was evaluated as the fEPSP mean slope at 60 min after the conditioning trains, normalized to the mean baseline slope [45, 56, 57]. To assess the effect of the IL-1β receptor antagonist (IL-1β-Ra) on LTP, slices were pre-incubated with IL-1β-Ra (100 ng/mL, from freshly-thawed stock in PBS/bovine-serum albumin 0.1%; R&D Systems) in oxygenated aCSF for 1 h and recorded as above.

Coronal slices (240 μm-thickness) were used for spine density analysis. CA1 pyramidal neurons were filled with biocytin during whole-cell patch clamp. Freshly weighted biocytin (0.2%; Tocris) was added to intracellular solution containing (in mM): Cs-methanesulfonate 120, CsCl 15, NaCl 8, HEPES 10, EGTA 0.20, TEA-Cl 10, QX314-Cl 5, Mg-ATP 2, Na-GTP 0.3 (~ 275–285 mOsm, pH 7.4). Patch-pipettes used for cell filling had a tip resistance of 4-10 MΩ and a minimum filling time of 10 min was used for each cell. Access resistance was monitored throughout this time to check for accessibility to the cytoplasm. To avoid cell damage after filling, the electrode was removed from the slice by establishment of an outside-out patch.

Spine density analysis

For analysis of biocytin-filled neurons, slices bearing neurons loaded with biocytin were fixed by immersion in 4% paraformaldehyde in PB (overnight, 4 °C). Then, slices were washed three times in PB and incubated with Streptavidin (1:750; Alexa Fluor 555-conjugated #S32355, Thermo Fisher; RRID:AB_2571525) and Green-Fluorescent Nissl-Stain (NeuroTrace 1:600; Invitrogen #N21480) in PB containing 0.3% Triton X-100 (overnight, 4 °C).

The Z-stack confocal images were captured using Nikon Eclipse Ti2 confocal microscope with 60x-oil objective and 4.5 digital zoom. We analyzed spines in the distal (terminal) apical dendrites.

Spine density was assessed by counting the number of spines in at least 18 segments per neuron (4 cells, 5 animals per experimental group) chosen in branch orders 2–4 of apical dendrites extending for an additional 30–60 μm away from the starting point [58]. Imaris software (9.8.2) was utilized to create 3D reconstructions of dendritic segments using the Filaments tool. The settings used for all reconstructions is the same as in [59]. An observer blinded to the experimental groups manually edited the reconstructions to include or exclude misidentified spines.

Behavioral Testing

All behavioral tests were conducted between 09:00 a.m. and 04:00 p.m.. Mice were habituated to the experimenter through daily handling sessions for one week prior to the onset of behavioral testing. In addition, animals were acclimated to the testing room for one hour immediately before the start of each experimental session.

To minimize potential olfactory interference, the chambers and objects were cleaned between animals and/or sessions using a 5% ethanol solution.

Open Field and Novel Object Recognition (NOR) Tests

Testing was performed in a dimly-lit (25 lx) plexiglass open field arena (60 × 60 × 30 cm), with dark-grey walls and white floor. On Day1 (D1), each mouse was placed in the arena center and allowed to freely-explore for 10 min, during which movements were recorded. We analyzed the time spent (s) in the arena center and periphery, and the total distance traveled. Thereafter, we conducted the NOR test, consisting of habituation, training and testing [60]. During habituation, mice were familiarized with the empty arena for 10 min (D2). 24 h later (D3), mice were trained for 10 min by exposure to two identical objects (yellow wooden spheres) placed in the arena center. Mice were then returned to their home cage. Following 24 h (D4), mice were returned to the arena for the test session (10 min), during which one object was replaced by a novel object (a light-grey wooden cone). In both the training and testing sessions the animals were left to freely-explore the objects, and the exploration time was recorded, calculated as the time when they touched or climbed on an object or sniffed it at a distance of at least 2 cm. The Object Discrimination Ratio (ODR) was calculated using the following formula (Eq. 2):

Objects were randomized and counterbalanced across groups.

Spatial Object Recognition (SOR) Test

The SOR test was conducted in the same circular arena previously described for the open field and NOR tasks. For this test, a high-contrast black-and-yellow striped cue was affixed to the inner wall of the arena to provide a visual local cue and enhance spatial orientation. Each mouse was tested individually across five consecutive 6-min sessions, with each session separated by a 3-min inter-trial interval in the home cage. In all sessions, animals were placed into the arena from the same starting location (protocol adapted from [61, 62]).

During session 1 (S1), mice were allowed to freely explore the empty apparatus, enabling familiarization with the environmental context and distal cues in the absence of objects. During sessions 2 to 4 (S2-S4), mice were exposed to four distinct objects (A-D) placed in fixed positions to allow the animals to encode the spatial configuration (habituation phase). The objects differed in shape, size, and material to promote discrimination and reduce object bias: (A) a yellow wooden ball, (B) a gray metal column, (C) a light-grey wooden cone, and (D) a glass jar with a perforated red cap.

Habituation to the spatial configuration was assessed by averaging the duration of contact with the four objects during sessions 2, 3, and 4 for each experimental group to provide an index of general exploratory activity. Object exploration was defined as the total time (s) the animal spent with its snout either in direct contact with the object or within approximately 2 cm of it.

Session 5 (S5) involved a spatial rearrangement: object A was moved to the previous location of object B, object B was placed in a novel, unoccupied position, while objects C and D remained in their original locations. This configuration was used to assess spatial novelty detection based on differential exploration of Displaced Objects (DO) versus Non-Displaced Objects (NDO), using the following formula (Eqs. 3 and 4):

These values were used to quantify the change in exploratory behavior elicited by the spatial rearrangement.

All sessions were video-recorded using a ceiling-mounted camera, and behavioral tracking was performed offline with EthoVision XT v.17.0 (Noldus).

Accelerated Rotarod Test

Motor coordination and motor learning were assessed using the accelerated rotarod test. The experimental procedure, performed over three consecutive days, consisted of two days of training followed by one test session on the third day (protocol adapted from [63]). The test was conducted using a computerized four-lane rotarod apparatus (Panlab, Harvard Apparatus), featuring a rotating cylinder (3 cm diameter) with independently controlled lanes, such that up to four mice could be tested simultaneously.

On the first day, mice underwent an acclimation phase consisting of a single 30 s trial on the rod rotating at a constant speed of 4 rpm. Subsequently, in each session, the rod acceleration was programmed to increase Linearly from 4 to 40 rpm over a 300 s period. Each session included four trials per mouse, separated by 5 min inter-trial intervals. The following behavioral parameters were measured for each trial: latency to fall (time in seconds spent on the rod) and the best performance across sessions, defined as the longest latency to fall on the final test day.

Power analysis, sample size, randomization, blinding

The sample number per group and experiment was determined by power analysis (G*Power software, 3.1.9.7v) using a power of 0.8 and errors of 0.05; standard deviations of all groups were obtained from previous publications with similar experiments.

Randomization was done with a random-number table to decide how mice from the same litter would be randomly assigned to the different groups.

Researchers were blinded to the animal group; un-blinding occurred after analysis.

The experimental units for each experiment are described in detail in Figure legends.

Statistical analysis

Analyses were performed using Prism8.01 (GraphPad). Data were checked for normality using the Shapiro–Wilk and D’Agostino-Pearson tests. Data from two groups (i.e., Sham/Casp3, Saline/6OHDA, WT/Tg2576, Tg Sham/Tg Casp3) were analyzed with Two-tailed parametric (unpaired t-test or Welch’s t-test) or non-parametric Mann–Whitney tests according to normality.

Sholl analysis data, PPR, I/O curves, mean exploration time during the training and test phases of the NOR test, mean exploration time during the familiarization and test phases of the SOR test, and mean latency to fall across sessions in the rotarod test were analyzed by Two-way Repeated-Measures (RM) ANOVA, using distance from soma, interval, stimulus intensity, object category (left vs right and novel vs familiar), test sessions (S1-4), object category (DO vs NDO), and number of sessions (S1-12) as repeated values, respectively. Post-hoc tests were performed using Sidak’s or Tukey’s multiple comparison tests.

Data from three or four groups were analyzed by One-Way ANOVA followed by Tukey’s multiple comparison test, or with Kruskal–Wallis followed by Dunn’s multiple comparison test.

For the differential expression analysis of transcriptomics expression, statistical significance was determined using the Wald test [64]. Cut offs (p < 0.050) were used for p values and for p values adjusted with the False Discovery Rate (FDR) methods of Benjamini–Hochberg and Benjamini-Yekutieli (FDR B&H and FDR B&Y, respectively).

See Figure legends for more details. p ≤ 0.05 indicates statistical significance. In box-and-whisker plots, the central line denotes the median, edges are upper and lower quartiles, whiskers show minimum and maximum values and points are individual experiments. In the violin plots used for spine density, the width of the plot at any given point corresponds to the frequency of data points at that value. The volcano plot for the transcriptomic analysis shows scattered individual data points. All other data are presented as mean ± s.e.m..

By Stuart Condie

  SYDNEY--Australia's ANZ Group scrapped its share buyback and plans to invest in mortgage and commercial bankers as its new CEO tries to boost productivity and returns. 

  ANZ on Monday said it would halt its ongoing share buyback, which has about 800 million Australian dollars, or US$518 million, remaining. This will allow it to return about A$1 billion in surplus capital to the bank, it said. 

  ANZ, which is Australia's fourth-largest bank by market capitalization, will invest heavily in its in-house mortgage sales force with the aim of increasing the number of lenders in its branches by up to 50%. 

  It also wants to increase the number of commercial bankers servicing its business and private customers by up to 50%. It plans to develop its own pipeline of bankers in a new Commercial Bankers Academy. 

  "Our people will deliver our strategy, and we must focus on a culture of customers, performance and talent," said Chief Executive Nuno Matos, who took charge this year. 

  Write to Stuart Condie at stuart.condie@wsj.com 

  (END) Dow Jones Newswires

  October 12, 2025 19:08 ET (23:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.

If you want to take a real-time sample of the global economy in action at any one moment, then the Cathay Cargo Hub at Hong Kong International Airport (HKG) is a particularly fascinating node. 
 
HKG is the world’s busiest air-cargo hub and no airline moves more freight through it – more than 1.7 million tonnes annually – than Cathay Pacific. Founded in 1946 as a cargo operator between Australia and China, Cathay now manages a sprawling 246,000 sq m hub and the constant hum of palletised and shrink-wrapped goods. In just one section of the warehouse, the inventory ranges from huge cases of Château d’Arche wine to Golden Lily mangoes from the Philippines, alongside priceless artworks packed in Cadogan Tate crates – all destined for the holds of windowless cargo freighters.
 
Air cargo accounts for less than one per cent of all goods shipped by tonnage globally but it makes up some 35 per cent of the total value. It carries all the things the world needs or wants in a hurry, from the latest iPhone and cold-chain pharma to Italian supercars and oil-drilling machinery. This urgency is just one of the reasons why air cargo is worth paying attention to: when people stop buying the things they need, it’s often a reliable signal that a recession might be on the horizon.

On a recent weekday morning, the warehouse was particularly active, catching up from the two-day stoppage enforced by Super Typhoon Ragasa, a level-10 storm that sideswiped Hong Kong. But the air-cargo world faces headwinds beyond the weather, including the unpredictable currents of geopolitics. 

Not long ago, air cargo prices were being driven upwards as a result of “fast fashion” purchases and other inexpensive goods from Chinese companies such as Shein and Temu. But after the Trump administration eliminated de minimis exemptions on goods worth less than $800 (€688) – precisely what Shein and Temu had exploited – US-bound air cargo from China – a key, typically one-way route – fell by at least 25 per cent.

“Supply chains don’t change overnight,” says Tom Owen, cargo director at Cathay Cargo. “But there has been a recalibration.” One benefit for air-cargo companies such as Cathay is that they don’t own factories – they own planes. This agility can work in their favour, as Cathay Group CEO Ronald Lam noted at the Routes World conference in Hong Kong, the day after the typhoon blew through. The uncertainty of tariffs, he said, created a “rush” to place orders. Air cargo, with its far shorter lead times compared with ocean shipping, “is really well positioned to capture that rush.” Hong Kong’s position as a global hub means that Cathay Group can adjust its routes swiftly. “We are getting more cargo from India and Southeast Asia, routed via Hong Kong to the US, to replenish the slowdown on US-bound cargo from China.”

During a week when the Trump administration threatened yet again to escalate the trade war that it began, air-cargo companies such as Cathay find themselves in the eye of the storm. But this is an industry in which agility and flexibility are key. During the coronavirus pandemic, cargo kept many airlines afloat as they quickly converted their passenger fleet into impromptu freighters, loading cargo where passengers normally sat. The latest disruptions present a new challenge but also a lesson. While long-term planning is crucial to success in business, the best strategies leave room to adapt. Take it from Cathay, which has dealt with its fair share of turbulence: be ready to change course quickly, even while mid-air.

Tom Vanderbilt is a regular Monocle contributor. For more opinion, analysis and insight, subscribe to Monocle today.

Perth, Australia (ABN Newswire) – OTC Markets Group Inc. (OTCMKTS:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced that Locksley Resources Ltd (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF), an exploration and development company focused on rare earths and antimony critical minerals, has qualified to trade on the OTCQX Best Market.

Highlights

– Locksley Resources Limited has qualified to trade on the OTCQX(R) Best Market, upgrading from the OTCQB(R) Venture Market

– Trading on OTCQX enhances Locksley’s visibility and accessibility to U.S. investors, supporting its U.S. focused critical minerals strategy

– Locksley’s flagship Mojave Project in California is strategically located adjacent to MP Materials’ Mountain Pass Mine, targeting rare earth elements (REEs) and antimony as part of a fully integrated mine-tomarket strategy

– The Company’s downstream technology partnerships underpin its role in re-establishing U.S. domestic supply chains for critical materials, with a particular focus on antimony

– Rare earths and Antimony are front and center in the global race to secure critical materials, with Locksley’s Mojave Project positioned at the heart of America’s efforts to restore domestic supply independence through a 100% U.S. mine-to-market strategy

Locksley has upgraded to OTCQX from the OTCQB Venture Market, and the symbol remains as “LKYRF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

The OTCQX Market is designed for established, investor focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Rare Earths & Antimony – Front and Centre in a Shifting Global Landscape

Locksley’s progression to the OTCQX comes amid escalating global focus on rare earth security, following new export restrictions and rising trade tensions. As nations move to safeguard access to critical materials, Locksley’s Mojave Project stands at the center of America’s effort to restore domestic supply independence. With a fully integrated mine-to-market strategy across antimony and rare earths, the Company is advancing a 100% American made approach that aligns directly with U.S. national policy priorities and the reshoring of strategic materials.

Nathan Lude – Head of Strategy, Capital Markets & Commercialisation commented

“Graduating to the OTCQX Market in record time since our initial listing just over three months ago, is a significant milestone for Locksley as we broaden our visibility and accessibility to U.S. investors. Our Mojave Rare Earths and Antimony Critical Minerals Project are strategically located in a tier-one jurisdiction adjacent to MP Materials’ Mountain Pass Mine. Locksley is positioned to play a pivotal role in re-establishing domestic supply chains through its mine-to-market strategy for critical materials, with a particular focus on antimony.”

About Locksley Resources Limited:

Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) is an ASX listed explorer focused on critical minerals in the United States of America. The Company is actively advancing exploration across two key assets: the Mojave Project in California, targeting rare earth elements (REEs) and antimony. Locksley Resources aims to generate shareholder value through strategic exploration, discovery and development in this highly prospective mineral region.

Mojave Project

Located in the Mojave Desert, California, the Mojave Project comprises over 250 claims across two contiguous prospect areas, namely, the North Block/Northeast Block and the El Campo Prospect. The North Block directly abuts claims held by MP Materials, while El Campo lies along strike of the Mountain Pass Mine and is enveloped by MP Materials’ claims, highlighting the strong geological continuity and exploration potential of the project area.

In addition to rare earths, the Mojave Project hosts the historic “Desert Antimony Mine”, which last operated in 1937. Despite the United States currently having no domestic antimony production, demand for the metal remains high due to its essential role in defense systems, semiconductors, and metal alloys. With significant surface sample results, the Desert Mine prospect represents one of the highest-grade known antimony occurrences in the U.S.

Locksley’s North American position is further strengthened by rising geopolitical urgency to diversify supply chains away from China, the global leader in both REE & antimony production. With its maiden drilling program planned, the Mojave Project is uniquely positioned to align with U.S. strategic objectives around critical mineral independence and economic security.

Tottenham Project

Locksley’s Australian portfolio comprises the advanced Tottenham Copper-Gold Project in New South Wales, focused on VMS-style mineralisation

About OTC Markets Group Inc.:

OTC Markets Group Inc. (OTCQX:OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX(R) Best Market, OTCQB(R) Venture Market, OTCID(TM) Basic Market and Pink Limited(TM) Market. Our OTC Link(R) Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading.

Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS(TM) are each SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

Source:
Locksley Resources Limited OTC Markets Group Inc.

Contact:
Locksley Resources Limited
T: +61 8 9481 0389
E: info@locksleyresources.com.au

1. The Activities overview page is all grown up

When the Activities overview page first appeared in LMS 5.0, we were thrilled to have a place to go to easily see all course activities — and their due dates, etc. — all in one place. When the Activities overview page debuted, only the Assignment activity was fully supported (teachers could easily see what they needed to grade, and learners could easily see what they needed to do).

But in LMS 5.1, this gets even better. Now the Activities overview page works across all the major activities — forums, quizzes, H5P, wikis, lessons, glossaries, even BigBlueButton sessions.

Why this matters: Instead of being just a tidy list, this page now acts like a real command centre. Teachers can see what needs grading or follow-up without digging around. Learners see their progress laid out clearly: what’s done, what’s next. That’s a big deal for reducing confusion.

PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ — Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (ex20ins) or uncommon non-ex20ins EGFR mutations and CNS involvement. Data will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, as a mini oral presentation on October 19 during the “NSCLC metastatic” session from 8:30 to 10 a.m. CEST.

The mini oral presentation will highlight preliminary efficacy and safety data from the CNS involvement cohort of the ongoing parallel cohort Phase 2b REZILIENT2 trial of zipalertinib.¹

Patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations represent a significant unmet medical need. An incidence of baseline brain metastases in EGFR ex20ins NSCLC patients ranging from 23% to 39% has been reported.² Patients with lung cancer with CNS involvement have a worse prognosis and require more aggressive therapy, including surgery and radiotherapy.

“Treatment options are limited for patients with NSCLC with EGFR mutations and active brain metastases,” said Helena A. Yu, MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer. “We are pleased to see that in approximately one-third of patients exposed to zipalertinib, a decrease in CNS lesions was observed. These preliminary results suggest the potential for zipalertinib to treat these patients, warranting future investigation.”

Authors will report results from the REZILIENT2 study of zipalertinib against active CNS metastases in patients with NSCLC harboring EGFR ex20ins or other uncommon mutations¹:

Summary of Preliminary Efficacy – by Investigator

As of the February 2025 data cutoff, 32 patients were enrolled in the CNS involvement cohort of the ongoing parallel cohort Phase 2b REZILIENT2 trial and received zipalertinib 100 mg orally twice daily. Patients received a median of 2 prior lines of therapy, and of all patients enrolled, 21 patients had ex20ins mutations and 13 patients had other uncommon mutations.

 As of the data cutoff, zipalertinib demonstrated:

• In the Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) criteria evaluable population with measurable CNS disease (n=16, including 3 patients with leptomeningeal disease (LMD), intracranial objective response rate was 31.3% including 1 intracranial complete response.
• In the same population, the intracranial disease control rate (iDCR) was 68.8% and the median intracranial duration of response (DOR) was 8.1 months.
• Measured in 29 of the cohort’s patients, preliminary systemic objective response rate (ORR) was 27.6% and median DOR was 7.6 months.
• Intracranial antitumor activity was found to be similar to its overall systemic anticancer activity in this cohort of patients.

Summary of Preliminary Safety and Tolerability

Administered at 100 mg orally twice daily, zipalertinib was found to be well tolerated, with no new safety signals observed.

Treatment-related adverse events of grade 3 or higher occurred in 8 patients (25%) and included anemia (n=3) and interstitial lung disease (n=2). There was one death due to interstitial lung disease.

About REZILIENT2
REZILIENT2 is a Phase 2b clinical trial (NCT05967689), evaluating the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring ex20ins mutations or other uncommon/single or compound EGFR mutations. Patients are enrolled into one of four cohorts: Cohort A (“prior ex20ins treatment”), Cohort B (“first-line”), Cohort C (“active brain metastases”), and Cohort D (“other uncommon EGFR mutations”). Cohort C includes patients harboring EFGR ex20ins or other uncommon/single or compound EGFR mutations and CNS involvement. In this cohort, patients may or may not have had prior treatment for advanced disease. Patients are treated with oral zipalertinib 100 mg twice daily. The primary endpoint is ORR and confirmed per investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and the secondary endpoints include DOR, DCR, PFS, OS, intracranial efficacy by RANO-BM criteria, PK and safety.

About Zipalertinib
Zipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with ex20ins mutations, while sparing wild-type EGFR. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib has received Breakthrough Therapy Designation from the FDA. Zipalertinib is investigational and has not been approved by any health authority.

Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.

About Taiho Oncology, Inc.
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.

For more information, visit https://www.taihooncology.com/, and follow us on LinkedIn and X.

Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd.

About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding our plans regarding future data presentations, the clinical development and regulatory filing plan and timeline of zipalertinib, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any NDA or other regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Contacts

Taiho Oncology

Leigh Labrie
(609) 664-9878
[email protected]

Cullinan Therapeutics

Investors 
Nick Smith
+1 401.241.3516
[email protected]

Media
Rose Weldon
+1 215.801.7644
[email protected]

References

1. K. Ohashi et al. Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations.
2. Remon J. et al. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. Cancer Treatment Review. Volume 90, November 2020, 102105.

SOURCE Taiho Oncology

Sign up here.

The firm noted that depletion for its Penfolds business “remains weak relative to plan”, with the firm now no longer retaining its guidance for the same for low to mid double-digit EBITS growth in fiscal 2026 and approximately 15% EBITS growth in fiscal 2027.

Similarly, given the uncertain outlook around trading conditions and expectations, Treasury Wine said it is prudent to pause the buyback until greater clarity is available.

“Several initiatives are now being implemented to mitigate the expected impacts in China in F26, including pursuing opportunities to re-allocate product to select customers in other key markets in a manner that is sustainable and minimises the risk of parallel imports back into the China market,” the winemaker added in its statement.

($1 = 1.5382 Australian dollars)

Our Standards: The Thomson Reuters Trust Principles., opens new tab

By David Winning

  SYDNEY--Mining software company RPM Global said it has agreed to a takeover by U.S. giant Caterpillar that values its equity at some 1.12 billion Australian dollars (US$730 million). 

  RPM Global said Caterpillar is offering A$5.00 per share in cash. That represents a 33% premium to RPM Global's share price on Aug. 28, just before it announced Caterpillar was interested in acquiring the company. 

  Denise Johnson, Caterpillar's president of Resource Industries, said RPM Global's software complements its own technologies, especially in areas such as asset management, fleet management and autonomy. 

  "Together, we have the potential to enhance mine site operations for our customers, unlocking even greater value," Johnson said. 

  Write to David Winning at david.winning@wsj.com 

  (END) Dow Jones Newswires

  October 12, 2025 17:50 ET (21:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.

Story Continues

The MAS uses the exchange rate as its policy tool to curb inflation and support growth, given Singapore’s trade-dependent economy. Separately, Singapore will also release its September nonoil domestic exports data on Friday.

  Malaysia 

  Malaysia will release third-quarter advance GDP figures and September trade data. Economic growth likely slowed to 4.3% in the third quarter from 4.4% in the previous quarter, as leading indicators point to weaker private consumption and softer imports of consumer goods, ANZ economists said. 

  While business approvals rose sharply in the first half, sentiment weakened in the third quarter across manufacturing and services, and slower capital goods imports suggest softer investment growth. Nominal imports fell faster than exports, likely improving net export slightly, though external demand remains subdued, ANZ added. The bank maintained its full-year growth forecast at 4.3%. 

  Malaysia's export growth may remain subdued in September amid global uncertainty and U.S. tariffs imposed in August, said TA Securities analyst Farid Burhanuddin. However, Malaysia's diversified export base, particularly strong trade ties with Asean, China, and other emerging markets, should help offset weaker U.S. demand, he added. 

  India 

  India will release inflation data on Monday, which is widely expected to show that price growth has resumed cooling after an uptick in August. A CPI print below the central bank's target could fuel expectations for more rate cuts ahead. 

  DBS economists forecast headline inflation to have eased to 1.5% on year in September from 2.1% the month before, taking the quarterly average slightly below the RBI's projected 1.8%. 

  "Global energy prices have also been subdued, offsetting the spillover risks from a weak rupee, while precious metals continue to stay buoyant," they said. 

  Wholesale price index data on Tuesday will round out the inflation picture. On Wednesday, attention will turn to trade figures for September, as India remains in talks with the U.S. over tariffs. DBS economists expect exports to moderate, leaving the trade deficit wide at $24 billion. 

  Any references to days are in local times. 

  Write to Emese Bartha at emese.bartha@wsj.com and Jihye Lee at jihye.lee@wsj.com 

  (END) Dow Jones Newswires

  October 12, 2025 17:14 ET (21:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.